Nuvation Bio Inc (NUVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Nuvation Bio Inc (NUVB) Financials: Revenue, Profit and Cash Flow
Nuvation Bio reported revenue of $62.90M for the fiscal year ended Dec 31, 2025. That year, net income was -$204.63M with a net margin of -325.3%, operating cash flow was -$173.43M and free cash flow was -$181.78M. The quarter ended Sep 30, 2026 had revenue of $44.95M and net income of -$41.90M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $62.90M | N/A | 100.0% | -338.7% | -325.3% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | N/A | N/A | N/A | N/A | N/A |
| Dec 2018 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $62.90M | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Gross profit | $62.90M | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Research and development | $115.11M | $524.19M | $71.29M | $87.81M | $69.04M | $32.60M | $25.11M | $482.67K |
| Operating income | -$213.06M | -$592.63M | -$99.82M | -$119.73M | -$93.32M | -$43.55M | -$32.10M | -$992.00K |
| Net income | -$204.63M | -$567.94M | -$75.80M | -$104.20M | -$86.85M | -$41.66M | -$33.55M | -$992.00K |
| EBITDA | N/A | N/A | N/A | -$106.55M | -$84.95M | N/A | -$32.09M | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.95M | $31.69M | $83.23M | $41.87M | $13.12M | $4.83M | $3.08M | -$2.16M | $727.00K | $1.44M | $0 | $264.00K |
| Gross profit | $44.95M | $31.69M | $83.23M | $49.88M | $13.12M | $4.83M | $3.08M | $700.00K | -$788.00K | $88.00K | $0 | $209.00K |
| Operating income | -$42.21M | -$51.04M | $3.88M | -$34.04M | -$56.43M | -$63.59M | -$59.00M | -$53.94M | -$48.10M | -$470.38M | -$20.20M | -$20.83M |
| Net income | -$41.90M | -$62.84M | $5.40M | -$36.59M | -$55.79M | -$59.01M | -$53.24M | -$49.45M | -$41.21M | -$462.49M | -$14.79M | -$13.79M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $52.93M by $111.15M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $594.82M | $540.63M | $621.48M | $672.14M | $776.15M | $221.79M | $120.95M | $158.00K |
| Current assets | $571.52M | $526.25M | $616.43M | $667.32M | $772.07M | $220.68M | $119.89M | $158.00K |
| Cash and equivalents | $164.09M | $35.72M | $42.65M | $101.10M | $132.42M | $29.75M | $3.47M | $138.00K |
| Total liabilities | $289.11M | $76.84M | $16.36M | $17.07M | $30.15M | $6.71M | $3.20M | $902.00K |
| Short-term debt | $5.72M | $6.28M | $0 | $1.21M | $863.00K | N/A | N/A | $600.00K |
| Long-term debt | $47.21M | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $305.72M | $463.79M | $605.12M | $655.08M | $746.00M | $215.08M | $117.75M | -$744.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $778.39M | $744.50M | $610.24M | $594.82M | $601.56M | $647.23M | $492.49M | $540.63M | $571.58M | $594.80M | $613.13M | $621.48M |
| Total liabilities | $550.42M | $490.64M | $290.68M | $289.11M | $275.68M | $274.32M | $73.03M | $76.84M | $68.86M | $62.66M | $19.08M | $16.36M |
| Cash and equivalents | $153.77M | $258.60M | $125.39M | $164.09M | $98.90M | $247.97M | $47.98M | $35.72M | $30.04M | $34.28M | $34.51M | $42.65M |
| Shareholder equity | $227.97M | $253.86M | $319.56M | $305.72M | $325.88M | $372.91M | $419.46M | $463.79M | $502.71M | $257.19M | $594.04M | $605.12M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$173.43M | -$130.41M | -$68.00M | -$96.11M | -$68.19M | -$36.53M | -$24.43M | -$616.00K |
| Capital expenditures | $8.35M | $162.00K | $69.00K | $370.00K | $282.00K | $145.00K | $659.00K | $659.00K |
| Free cash flow | -$181.78M | -$130.57M | -$68.07M | -$96.48M | -$68.47M | -$36.67M | -$25.09M | -$1.27M |
| Investing cash flow | $99.52M | $122.70M | $8.92M | $63.46M | -$454.67M | -$70.32M | -$115.86M | -$115.86M |
| Financing cash flow | $202.53M | $331.00K | $628.00K | $1.33M | $625.53M | $133.13M | $143.62M | $800.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$38.56M | -$42.97M | $5.07M | -$29.73M | -$52.89M | -$48.18M | -$42.63M | -$46.30M | -$31.09M | -$37.32M | -$15.70M | -$15.03M |
| Capital expenditures | $1.59M | $254.00K | $48.00K | $89.00K | $8.01M | $181.00K | $72.00K | $13.00K | $148.00K | $0 | $27.00K | $13.00K |
| Free cash flow | -$40.15M | -$43.22M | $5.02M | -$29.82M | -$60.90M | -$48.36M | -$42.70M | -$46.31M | -$31.23M | -$37.32M | -$15.73M | -$15.04M |
Frequently Asked Questions About NUVB
What is Nuvation Bio's annual revenue?
Nuvation Bio reported revenue of $62.90M for the fiscal year ended Dec 31, 2025.
Is Nuvation Bio profitable?
No. Nuvation Bio reported net income of -$204.63M for the fiscal year ended Dec 31, 2025, with a net margin of -325.3%.
How much free cash flow does NUVB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$173.43M minus capital expenditures of $8.35M produced free cash flow of -$181.78M.
How much debt does Nuvation Bio have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $47.21M, short-term debt of $5.72M and cash and equivalents of $164.09M.
What is NUVB's profit margin?
For the fiscal year ended Dec 31, 2025, Nuvation Bio reported gross margin of 100.0%, operating margin of -338.7% and net margin of -325.3%.
NUVB pages: Overview, Earnings, Forecast, Financials, Competitors